Stocks Health care TXMD
NASDAQ · Health careTherapeuticsMD, Inc. (TXMD)
TherapeuticsMD, Inc. brought in $3.3M of revenue over the twelve months to June 30, 2026, up 27.8% from a year earlier. It posted a net loss of $217K. At June 30, 2026 it held $9.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
What TherapeuticsMD, Inc. does
TherapeuticsMD, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker TXMD.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $3M | -$569K | -$0.05 | n/a |
| 2024 | $1.8M | -$2.2M | -$0.19 | n/a |
| 2023 | $1.3M | -$10.3M | -$0.99 | n/a |
| 2022 | $70M | $112M | $11.96 | n/a |
| 2021 | $2.6M | -$172.4M | -$21.66 | -$142.7M |
| 2020 | $64.9M | -$183.5M | -$33.75 | -$159.7M |
Full financial statements: income, balance sheet and cash flow
Where TXMD ranks in Health care
Latest SEC filings
What TherapeuticsMD, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 11, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 8.7% to $869K versus the same quarter last year; diluted EPS $0.01 versus $0.05.
- August 11, 2026
- August 5, 2026Passive stake changed SCHEDULE 13G/A
- May 12, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 84% to $724K versus the same quarter last year; diluted EPS $0.01 versus -$0.06.
- May 12, 2026
- April 6, 2026Passive stake (5% or more) SCHEDULE 13G
- April 1, 2026Annual report (amended) 10-K/A · period to December 31, 2025Revenue rose 72% to $3M versus the prior year; diluted EPS -$0.05 versus -$0.19.
- April 1, 2026Late annual report notice NT 10-K
- March 30, 2026
- March 30, 2026Annual report 10-K · period to December 31, 2025Revenue rose 72% to $3M versus the prior year; diluted EPS -$0.05 versus -$0.19.
Who owns TXMD
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Rubric Capital Management LP13D, may seek influence with 1 related filers | 25.73% | November 17, 2023 |
| Baselake Partners, LP13G, passive with 2 related filers | 6.8% | August 5, 2026 |
| Clearline Capital LP13G, passive with 2 related filers | 5.5% | February 12, 2025 |
Largest institutional holders
Insiders
Questions about TXMD
What does TherapeuticsMD, Inc. do?
TherapeuticsMD, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker TXMD.
Is TherapeuticsMD, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $217K on revenue of $3.3M.
How much revenue does TherapeuticsMD, Inc. make?
Over the twelve months to June 30, 2026 TherapeuticsMD, Inc. reported revenue of $3.3M. That is 27.8% more than a year earlier.
When did TherapeuticsMD, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026.
Similar companies
Compare TXMD with
Follow TXMD
Get an email when TherapeuticsMD, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow TXMD: get an email when it filesWhere the numbers come from
Financial figures are the values TherapeuticsMD, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.